PODD Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 14.91%. Insulet Corp.'s return on equity of 18.92% beat Boston Scientific Corp.'s return on equity of 12.46%.

Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 28.32%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 28.7%. Given that Boston Scientific Corp. has higher upside potential than Insulet Corp., analysts believe Boston Scientific Corp. is more attractive than Insulet Corp..

Insulet Corp. has a beta of 1.400, which suggesting that the stock is 39.975% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Insulet Corp.'s net income of $87.6M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Insulet Corp.'s price-to-earnings ratio is 85.40x while Boston Scientific Corp.'s PE ratio is 52.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.45x versus 7.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 15.47%. Insulet Corp.'s return on equity of 18.92% beat Globus Medical, Inc.'s return on equity of 10.08%.

Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 28.32%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 5.83%. Given that Insulet Corp. has higher upside potential than Globus Medical, Inc., analysts believe Insulet Corp. is more attractive than Globus Medical, Inc..

Insulet Corp. has a beta of 1.400, which suggesting that the stock is 39.975% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Globus Medical, Inc. quarterly revenues of $769M. Insulet Corp.'s net income of $87.6M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Insulet Corp.'s price-to-earnings ratio is 85.40x while Globus Medical, Inc.'s PE ratio is 30.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.45x versus 4.64x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 28.31%. Insulet Corp.'s return on equity of 18.92% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 28.32%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 1.14%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..

Insulet Corp. has a beta of 1.400, which suggesting that the stock is 39.975% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Insulet Corp.'s net income of $87.6M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Insulet Corp.'s price-to-earnings ratio is 85.40x while Intuitive Surgical, Inc.'s PE ratio is 78.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.45x versus 22.43x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of -8.49%. Insulet Corp.'s return on equity of 18.92% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 28.32%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 5.39%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..

Insulet Corp. has a beta of 1.400, which suggesting that the stock is 39.975% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Insulet Corp.'s net income of $87.6M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Insulet Corp.'s price-to-earnings ratio is 85.40x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.45x versus 1.56x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.